Knight Therapeutics | GUD - Ordinary Share Capital


Knight Therapeutics reported CAD99.68M in Ordinary Share Capital for its fiscal quarter ending in September of 2025.





Ordinary Share Capital Change Date
Acasti Pharma USD 1000 261.04M Dec/2024
Akebia Therapeutics USD 265.42M 199K Dec/2025
Alaunos Therapeutics USD 2.38M 172K Mar/2026
Aurora Cannabis CAD 58.95M 2.24M Mar/2026
Canopy Growth CAD 422.07M 53.78M Mar/2026
Cronos Group USD 370.73M 5.53M Jun/2026
Dianthus Therapeutics USD 54.58M 11.36M Mar/2026
Ionis Pharmaceuticals USD 165.64M 265K Jun/2026
IQVIA Holdings USD 164.6M 2.3M Jun/2026
Knight Therapeutics CAD 99.68M 24.66K Sep/2025
Moderna USD 391M 2M Sep/2025
Omeros USD 611K 17K Dec/2023
Organigram Holdings CAD 136.47M 1.34M Mar/2026
Organon & Co USD 262.61M 40K Jun/2026
Revvity USD 111.63M 174K Jun/2026
Tectonic Therapeutic USD 18.83M 92.19K Mar/2026
Tilray USD 116.52M 5.01M Sep/2025
Viatris USD 1.16B 9.19M Jun/2026
Xeris Pharmaceuticals USD 172.56M 6.34M Mar/2026